SCN1A rs3812316: Understanding Your Genetic Variant
The rs3812316 variant is a genetic change located within the SCN1A gene, which provides instructions for building sodium channels in the brain. Research suggests this variant may be associated with differences in how individuals respond to certain anti-epileptic medications, such as phenytoin.
What each genotype means
Typical SCN1A genotype
This is the most common genotype observed in the general population. Research into this specific variant has yielded mixed results regarding its influence on phenytoin or carbamazepine serum levels and dosage requirements, with some studies suggesting an association while others have found no significant clinical impact. Please discuss your medication management and any concerns about drug efficacy or side effects with your clinician or pharmacist.
This is the most frequent genotype found across all major global populations.
Heterozygous SCN1A variant
You carry one copy of the variant allele. While some early research suggested this variant might influence how the body processes anti-epileptic drugs like phenytoin, subsequent studies have been inconsistent and have not consistently confirmed a clinical impact on drug response. Always consult with your healthcare provider before making any changes to your prescribed medication regimen.
This genotype is common and found in a significant portion of individuals across diverse ancestral backgrounds.
Homozygous SCN1A variant
You carry two copies of the variant allele. Current scientific literature provides conflicting evidence regarding whether this genotype significantly alters the maintenance dose or serum levels of medications such as phenytoin. Because the clinical significance remains debated and not well-established, you should rely on clinical monitoring by your doctor rather than this genetic result to guide your treatment.
This genotype is less common than the GG or GA genotypes but is present in most populations worldwide.
What is rs3812316 and Where is it Located?
The identifier rs3812316 refers to a specific single nucleotide polymorphism (SNP) located within the SCN1A gene. A SNP is a common type of genetic variation where a single "letter" of the DNA code—a nucleotide—differs between individuals. In the context of the human genome, rs3812316 represents a specific position where different people may carry different DNA bases. This variant is situated within the SCN1A gene, which is located on chromosome 2. Because this variant is common, it is found in many people across diverse ancestral backgrounds. Scientists study these variations to understand why individuals may have different physiological responses to environmental factors, including pharmaceutical treatments. By mapping these variations, researchers can better understand the complex relationship between our inherited genetic code and the way our bodies process medications used to manage neurological conditions.
The Role of the SCN1A Gene
The SCN1A gene is essential for the proper function of the nervous system. It encodes the alpha subunit of a voltage-gated sodium channel, known as NaV1.1. These channels act like tiny gates in the membranes of nerve cells, allowing sodium ions to flow in and out. This movement of ions is critical for generating and transmitting electrical signals throughout the brain. When these channels function correctly, they help regulate the excitability of neurons, ensuring that electrical impulses are sent at the right time and intensity. Because of its central role in brain signaling, the SCN1A gene is a major focus in epilepsy research. Mutations or variations in this gene can alter the behavior of these sodium channels, potentially affecting how neurons communicate and how the brain responds to anti-epileptic drugs that target these specific channels.
Research Associations and Evidence Strength
Scientific research has investigated the link between SCN1A variants and the efficacy of anti-epileptic drugs. Specifically, studies have explored whether certain genotypes at this locus correlate with serum levels of medications like phenytoin. The evidence suggests that genetic variation in SCN1A may influence the pharmacodynamics of these drugs, meaning the way the drug interacts with the body to produce its effect. While some studies have identified statistical associations between SCN1A polymorphisms and drug response, it is important to note that "association" does not mean "causation." Many factors, including age, liver function, other medications, and the specific type of epilepsy, play significant roles in how a patient responds to treatment. The evidence for rs3812316 is considered a subject of ongoing pharmacogenomic study, and clinicians use this information as one of many tools to help optimize patient care.
Population Frequency
The rs3812316 variant is considered a common polymorphism, meaning it is found at significant frequencies across various global populations. Genetic databases indicate that the different alleles for this SNP are present in most ancestral groups, reflecting the natural diversity of the human genome.
What You Can and Cannot Do With This Information
Understanding your genetic profile can be an empowering step in your health journey, but it must be approached with caution. You can use this information to have a more informed conversation with your neurologist or pharmacist about your treatment plan. If you are taking anti-epileptic medication, you might ask your doctor if pharmacogenomic testing is relevant to your specific clinical situation. However, you cannot use this information to diagnose yourself, change your medication dosage, or stop taking prescribed drugs on your own. Genetic variants are only one piece of a much larger clinical puzzle. Any decisions regarding your medical treatment must be made in consultation with a qualified healthcare professional who can interpret your genetic results in the context of your full medical history, current symptoms, and other laboratory findings.
How common is this variant?
The rs3812316 variant is common across all major global populations, with its various genotypes appearing frequently in diverse ancestral groups.
Frequently asked questions
Does having a specific SCN1A genotype mean I have epilepsy?
No. The rs3812316 variant is a common genetic polymorphism found in many healthy individuals. It is not a diagnostic marker for epilepsy.
Should I change my medication based on my SCN1A results?
Absolutely not. Never change your medication dosage or stop taking your prescribed treatment without consulting your doctor, as this could lead to serious health risks.
What is pharmacogenomics?
Pharmacogenomics is the study of how your genes affect your body's response to medications. It helps doctors understand why some people respond well to a drug while others may experience side effects or require different doses.
Where can I get tested for this variant?
Genetic testing for pharmacogenomic markers is typically ordered by a healthcare provider if they believe it will assist in your clinical management. You should discuss the necessity and utility of such testing with your neurologist.
Sources & further reading
Educational information only, last refreshed 9/30/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs3812316?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SCN1A
Variant assessed for responsiveness to sodium-channel-blocking antiepileptic drugs.
This variant in the SCN1A gene influences sodium channel expression and has been associated with altered dose requirements and clinical response to anti-seizure medications including phenytoin and carbamazepine.
Intronic regulatory variant in SCN1A associated via clinical PGx studies with altered therapeutic dosing requirements and pharmacoresistance to carbamazepine and phenytoin.